Holen Sie sich die Stockscreener-App
3.02
2.27%
-0.07
Handel nachbörslich:
3.02
Schlusskurs vom Vortag:
$3.09
Offen:
$3.05
24-Stunden-Volumen:
239.57K
Relative Volume:
0.15
Marktkapitalisierung:
$79.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-40.19M
KGV:
-1.2882
EPS:
-2.3444
Netto-Cashflow:
$-38.49M
1W Leistung:
-2.58%
1M Leistung:
-2.89%
6M Leistung:
-64.84%
1J Leistung:
-69.31%
1-Tages-Spanne:
$3.00
$3.085
1-Wochen-Bereich:
$3.00
$3.205
52-Wochen-Spanne:
$2.66
$16.00
Elicio Therapeutics Inc Stock (ELTX) Company Profile
Firmenname
Elicio Therapeutics Inc
Sektor
Branche
Telefon
(857) 209-0050
Adresse
451 D STREET, 5TH FLOOR, BOSTON
Compare ELTX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
3.02 | 81.21M | 0 | -40.19M | -38.49M | -2.3444 |
VRTX
Vertex Pharmaceuticals Inc
|
515.57 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.86 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
986.80 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
211.94 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
362.66 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
Elicio Therapeutics Inc Stock (ELTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2026-03-10 | Eingeleitet | Rodman & Renshaw | Buy |
Elicio Therapeutics Inc Aktie (ELTX) Neueste Nachrichten
ELTX Stock Heads For Worst Day Ever — Elicio Therapeutics' Pancreatic Cancer Data Disappoints - Stocktwits
Elicio Therapeutics (NASDAQ:ELTX) Stock Rating Upgraded by Wall Street Zen - marketbeat.com
Elicio Therapeutics (ELTX) Stock Forum and Discussion - Moomoo
Elicio Therapeutics: Q2 Earnings Snapshot - AOL.com
Elicio Therapeutics Q2 Results: EPS beats estimate, losses narrow 35% YoY - scanx.trade
Elicio Therapeutics (NASDAQ:ELTX) Announces Earnings Results - marketbeat.com
Elicio Therapeutics (ELTX) faces going-concern risk after $20M loss and trial miss - Stock Titan
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall - TradingView
Elicio Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Updates - manilatimes.net
Elicio Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView
Elicio Therapeutics Announces Activation of the Investigator-Initiated Phase 1 Study of Neoadjuvant ELI-002 7P for Pancreatic Ductal Adenocarcinoma - manilatimes.net
Elicio Therapeutics Announces Opening of MSK-Led Phase 1 Neoadjuvant Study of ELI-002 7P in Resectable Pancreatic Cancer - Quiver Quantitative
Elicio Therapeutics Announces Activation of the - GlobeNewswire
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation int - The National Law Review
ELTX Q2'26 Earnings: EPS estimate is (0.54) USD - TradingView
(ELTX) Volatility Zones as Tactical Triggers - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Aga - The National Law Review
Certain Stock Options of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026. - marketscreener.com
Certain Warrants of Elicio Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 6-AUG-2026. - marketscreener.com
Elicio Therapeutics Inc expected to post a loss of 54 cents a shareEarnings Preview - TradingView
ELTX Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Elicio Therapeutics (ELTX) Expected to Post Earnings on Thursday - marketbeat.com
Elicio Therapeutics (NASDAQ:ELTX) Stock Price Down 1.7%Here's What Happened - marketbeat.com
Price to sales ratio of Elicio Therapeutics, Inc – HAM:9HA - TradingView
Elicio Therapeutics Inc (ELTX) Cash Flow - TradingKey
ELTX|Elicio Therapeutics Inc|Price:3.000| - TradingKey
Elicio Therapeutics Inc (ELTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Elicio Therapeutics Inc (ELTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Elicio Therapeutics Market Sentiment - Benzinga
Elicio Therapeutics Inc (ELTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Elicio Therapeutics Inc (ELTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ELTX|Elicio Therapeutics Inc|Price:3.000|Chg%:-0.150 - TradingKey
TradingKey - TradingKey
Elicio Therapeutics, Inc. Revenue Breakdown – NASDAQ:ELTX - TradingView
Elicio Therapeutics Inc (ELTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Form 4 Elicio Therapeutics Inc For: 17 July By Investing.com - Investing.com Nigeria
Ladenburg Thalmann initiates coverage of Elicio Therapeutics (ELTX) with buy recommendation - MSN
Elicio Therapeutics (ELTX) awards 64,643 stock options to R&D and medical chief - Stock Titan
Elicio Therapeutics (ELTX) grants 52,832 stock options to Chief Scientific Officer - Stock Titan
Elicio Therapeutics (ELTX) awards 60,833 stock options to its CFO - Stock Titan
Elicio Therapeutics (ELTX) CEO awarded 186,944 stock options at 3.2000 - Stock Titan
Moti Investments discloses 6.1% stake in Elicio Therapeutics (NASDAQ: ELTX) - Stock Titan
RANI Stock Price and Chart — NASDAQ:RANI - TradingView
Price-Driven Insight from (ELTX) for Rule-Based Strategy - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elicio Therapeutics, Inc. (ELTX) And Encourages Shareholders to Connect - ACCESS Newswire
Enterprise value to revenue forward of Elicio Therapeutics, Inc. – NASDAQ:ELTX - TradingView
ELTX Stock Price, Quote & Chart - ChartMill
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elicio Therapeutics, Inc. (ELTX) And Encourages Shareholders to Reach Out - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Elicio Therapeutics, Inc.ELTX - PR Newswire
Why Is ELTX Stock Falling Today? - Stocktwits
Finanzdaten der Elicio Therapeutics Inc-Aktie (ELTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.20%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):